+220.6%
AEM vs MRNA
-27.3%
+247.9%
-45.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.4% | -2.2% | -2.2% | -4.2% |
| 7D | -15.2% | -12.7% | -2.5% | -14.3% |
| 30D | -19.2% | -20.7% | +1.4% | -17.8% |
| 3M | -28.5% | +46.3% | -74.8% | -30.8% |
| 6M | -14.7% | +305.2% | -319.9% | -28.2% |
| YTD | -10.2% | +561.2% | -571.4% | -27.3% |
| 1Y | -3.8% | +772.1% | -775.9% | -23.6% |
| 3Y | +227.5% | +147.0% | +80.6% | +175.8% |
| All | +220.6% | -27.3% | +247.9% | +190.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling